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IL-3 is known to promote the growth and differentiation ofhemopoietic progen-
itors of the erythroid and myeloid lineages (1, 2). Availability of the recombinant
purified protein has led to an examination of its potential as a therapeutic agent
for hematological disorders. Since we have recently developed a model ofan acute,
lethal form ofanemia caused byasingle injection ofa monoclonal anti-mouse RBC
(anti-MRBC) autoantibody derived from autoimmune NZB mice (3), we evaluated
the protective effect ofmurine rIL-3; this effect was compared with that of recom-
binant erythropoietin (rEpo) and granulocyte-macrophage CSF (rGM-CSF). Our
results indicate that perfusion of murine rIL-3 completely prevents death due to
acute anemia induced by the anti-MRBC mAb. This beneficial effect contrasted
with the partial or absent effect ofrEpo and rGM-CSF perfusion.
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Materials and Methods
BriefDefinitive Report
In Vivo Perfusion ofrIL-3, rGM-CSF, or rEpo.
￿
Escherichia coli murine rIL-3, prepared as de-
scribed previously (1), contained <1 ng/mlof LPS. Murine rGM-CSF (4) and human rEpo
(5) were kindly provided by Dr. J. J. Mermod, GLAXO S. A., Geneva, Switzerland, and
Chugai Pharmaceutical Co., Ltd., Shizuoka,Japan, respectively. Alzet osmotic minipumps
(model 2002; Alza Corp., Palo Alto, CA), loaded with rIL-3 (20 ug), rGM-CSF(20 lug), and
rEpo (2 ug) in PBS containing 10% (vol/vol) glycerol, or PBS containing 10% glycerol and
10 ng/ml LPS as a control, were placed subcutaneously in 3-4-mo-old (C57BL/10 x
BALB/c)F, (B10 x BALB) mice. The presence of circulating rIL-3 or rGM-CSF in perfused
animals was controlled by IL-3- or GM-CSFspecific bioassay, as described previously (6).
Epo activity in sera was determined by their ability to maintain the growth of a FDC-P2
cell line, as described (7). The specificity of the bioassays was controlled in the presence of
rabbit anti-IL-3 (6), anti-GM-CSF(6), and/or anti-Epo (akind gift of Dr. S. Kamachi, Chugai
Pharmaceutical Co., Ltd.) antibodies.
Anti-MRBC mAb and Hematocrit (Ht) Determination.
￿
An IgG1 monoclonal anti-MRBC auto-
antibody (31-9D)(3)wasprepared by cell fusion ofNS-2 myelomacell line and spleen cells from
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unmanipulated NZB mice. Culture supernatant concentrated by precipitation in 50% satu-
rated ammonium sulfate, containing -300 Ag 31-9DmAb, was used for intraperitoneal injec-
tion. Hts were determined by centrifugation for 5 min at 12,000 rpm of blood samples in hep-
arinized microhematocrit tubes (Clay Adams; Becton Dickinson & Co., Mountain View, CA).
Histopathology.
￿
Spleens and livers were obtained at autopsy, processed for histological ex-
amination, and stained with hematoxylin and eosin.
Opsonization ofMRBC with Anti-MRBCmAb.
￿
5ml ofculture supernatant containing -100
t~g of 31-9D anti-MRBC mAb was incubated with 250 td of 25% MRBC suspension freshly
prepared from BALB/c mice. After an overnight incubation at 4°C, and washing three times
with PBS, a 25% suspension of opsonized MRBC in PBS was prepared.
In Vitro Fc Receptor-mediated Phagocytosis.
￿
3 x 105 peritoneal cells from unmanipulated
BALB/c mice in 3 ml of DME were allowed to adhere to 6-well plates (Falcon Labware, Ox-
nard, CA) by a 1-h incubation at 37°C. After washing, adherent macrophages were incubated
for 3 d in the presence or absence of rIL-3 or rGM-CSF (100 ng/ml/d) in DME supplemented
with additional amino acids (6), insulin (15 ug/ml), transferrin (1.5 hg/ml), testosterone (2 mM),
linoleic acid (1 ug/ml), 5 x 10 -5 M 2-ME, and BSA (0.5 mg/ml). Then, 10 p,l of 25% op-
sonized MRBC were added and incubated for 20 min at 37°C. After extensive washings
with Hanks' medium, plates were treated with distilled water for 10 s to lyse extracellular
MRBC, and isotonicity was quickly restored by adding Hanks' medium. Phagocytic activity
was expressed by counting on phase-contrasted photographs the percentage of phagocytic
cells and the total number of phagocytosed MRBC per 100 cells.
Results and Discussion
Four groups of (B10 x BALB)F, mice received osmotic minipumps placed sub-
cutaneously and loaded with either murine rIL-3 (n = 12), murine rGM-CSF (n =
5), human rEpo (n = 12), or PBS (n = 12) as a control. 3 d later, mice received
a single intraperitoneal injection ofthe lethal dose (300 lAg) of monoclonal IgG1 anti-
MRBC autoantibody (31-9D). The injection of 31-9D anti-MRBC mAb in control
PBS-perfused mice rapidly induced a severe anemia, as documented by a rapid and
marked decrease in Ht values (Fig. 1 A). By 5 d, all the mice were dead from anemia
(Fig. 1 B). An identical mortality rate was observed in mice perfused with rGM-
CSF (Fig. 1 B), although they had somewhat lower Ht values 2 d after the anti-
MRBC rnAb injection (13.8 t 0.4%) than did control PBS-treated mice (18.3 ±
3.0%) (p <0 .005). Notably, mice perfused with rGM-CSF had detectable levels of
circulating GM-CSF (data not shown). In the group of mice perfused with rEpo,
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FIGURE 1.
￿
(A) Ht values ofPBS-(*)or rIL-3-(O) perfused mice after the injectionof anti-MRBC
mAb. (B) Survival curve of mice perfused with either rIL-3 (0---0), rGM-CSF (0-0),
rEpo (0-*), or PBS(A - 0) after a single intraperitoneal injection ofanti-MRBC mAb.SHIBATA ET AL.
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the anemia after the anti-MRBC mAb administration showed kinetics similar to
those of the control group of mice (Ht values: before the mAb injection, 49.3 ±
1.3%; 24 h after the injection, 23.5 ± 4.7%). Although the majority of mice died
of acute anemia by 7 d after the anti-MRBC mAb injection, 4 of 12 mice survived
and progressively recovered from anemia by 10 d(mean Ht values of survivingmice
at 10 d, 44.8 t 4.5%). It must be stressed that in mice suffering from anemia and
not perfused with rEpo, significant activity of Epo was detectable in sera 4 d after
the anti-MRBC mAb injection (data not shown). This indicated that the additional
exogenous supply of Epowasnot sufficient to insure full protection against the most
severe form of anemia, presumably because of the limited size of the pool of inter-
mediate and late erythroid precursors responsive to Epo. In contrast, the treatment
with rIL-3 almost completely protected the animals from deathdueto acute anemia
(Fig. 1 B). The Ht values of these mice were consistently higher than those of the
control group of mice (p <0.001) (Fig. 1 A). Ht values began to increase 4 d after
the anti-MRBC mAb injection, andprogressively returned to normal levels by 8-10 d.
Consequently, all but one mouse recovered from the acute severe form of anemia.
Histological examination revealed remarkable pathological changes in the spleens
andlivers of the mice that died of anemia. The anti-MRBC mAb injection induced
a threefold increase in splenic weight (292 ± 35 mg), as compared with untreated
control mice (98 t 18 mg); this corresponded on ahistological section to an enormous
accumulation ofagglutinated RBC, rendering the splenic architecture hardly recog-
nizable (Fig. 2A). In thelivers, agglutinated RBC accumulatedin sinusoids, causing
marked necrosis ofhepatic parenchymalcells (Fig. 2, CandD). Sinceerythrophagocy-
tosis by Kupffer cells or by splenic macrophages was hardly detectable, the major
cause of anemia was apparently themarked sequestration of agglutinated RBC, mostly
in spleen andliver. The findingthat erythrophagocytosiswas limited can be explained
by the fact that the mAb used in the present study is of the IgGl subclass, and that
the affinity of Fc receptor for IgGl/IgG2b is known to be very weak (8). In contrast,
the mice that recovered from the anemia due to the perfusion of rIL-3 did not show
splenic accumulation of agglutinated RBC (Fig. 2 B), although their spleens were
enlarged as a result of an expansion ofhemopoietic progenitors stimulated by rIL-3
(2, 3). Similarly, the histological appearance of their livers was essentially normal
(Fig. 2 E), except for the presence of a number of extramedullary hemopoietic foci
containing mostly cells from the erythroid and myeloid lineages. In contrast, the
spleens and livers of the mice that recovered from anemia after the rEpo perfusion
showed areas of fibrosis surrounding necrotic foci (Fig. 2, F, G, and H).
Since mice perfused with rIL-3 completely recovered from anemia without
significant fibrosis in spleensand livers, one ofthe beneficial effects ofrIL-3 on animals'
survival may be related to its enhancing activity of phagocytosis, as shown previ-
ously in mice injected with rIL-3 (2). To determine whether rIL-3 was indeed able
to stimulate macrophages to increase theirphagocytic activity of MRBC coated with
31-9D anti-MRBC mAb, resident peritoneal macrophages from BALB/c mice were
firststimulated in vitro with either rIL-3 or rGM-CSFfor 3 d, and then theirphago-
cytic activity of anti-MRBC mAb-coated MRBC was assessed. Macrophages in-
cubated with rIL-3 or rGM-CSF exhibited higher percentages of phagocytic cells
(82 and 89%, respectively) and phagocytosed larger numbers of antibody-coated
MRBC (303 and 375 MRBC per 100 macrophages, respectively) than did macro-1812
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FIGURE 2 .
￿
(A, C, andD) Representative histological appearance of spleen and liver from con-
trol PBS-perfused mice that died of acute anemia 4 d after the injection of anti-MRBC mAb .
Note an enormous accumulation of agglutinated RBC in entire spleen, which does not allow it
to recognize splenic structures (A ; HE, x 40), andmarked necrosis of hepatic parenchymal cells
(C; HE, x40) secondary to the accumulation of agglutinated RBC in sinusoids of liver (D ;
HE, x400). (B and E) Representative histological appearance of spleen and liver from rIL-3-
perfused mice that recovered from acute anemia induced by anti-MRBC mAb (10 d after the
anti-MRBC mAb injection) . Note complete absence of accumulation of agglutinated RBC in
spleen (B ; HE, x 40) and liver (E ; HE, x 40). (F, G, andH) Representative histological appear-
ance of spleen and liver from rEpo-perfused mice that recovered from acute anemia induced
by anti-MRBC mAb (10 d after the anti-MRBC mAb injection) . Note the presence of fibrosis
in spleen (F and G; HE x40 and x 100, respectively) and around necrotic focus in liver (H ;
HE, x 100) .
phages in the controlunstimulated culture (the percent of phagocytic cellswas 24%,
and the number of opsonizedMRBC phagocytosed by 100 macrophages was 107) .
This enhanced phagocytic activity of macrophages was mediated by Fcy receptor,
as shown by the complete inhibition in the presence ofa rat anti-Fcy receptor mAb
(2 .4G2) (9) (data not shown) .SHIBATA ET AL.
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The data presented here have demonstrated that rIL-3 perfusion is able to protect
animals from death due to an acute severe form of anemia induced by a monoclonal
IgGI anti-MRBC autoantibody, while only partial protection (one thirdof thecases)
by rEpo andlittle effect by rGM-CSF are observed. This protection couldbe related
to several effects of rIL-3 perfusion on hemopoietic cells. First, marked expansion
of early hemopoietic progenitors by rIL-3 treatment increases the accumulation of
intermediate and late erythroid progenitors responsive to Epo (1, 2). Because anemic
mice rapidly produce large amountsof Epo, as documented by the presence ofhigh
levels of circulating Epo, the increase in Epo-responsive precursors by the IL-3 per-
fusion is an important factor. The failure of rEpo and thelimited activity of murine
rGM-CSF to promote the proliferation and differentiation of early precursors of
the erythroid lineage (10) would explain the only partial protection exerted by rEpo
andthe absence of protective effect by rGM-CSF. Second, since severe liverdamage
due to an enormous accumulation of agglutinated RBC in sinusoids can also con-
tribute to the animals' death, the enhancement of macrophage phagocytic activity
by IL-3, as shownby others (2) and in our present study, maylead to efficient elimi-
nation of agglutinated MRBC by Kupffer cells or splenic macrophages. The pro-
motion of the proliferation and differentiation of monocyte/macrophage lineage by
rIL-3 perfusion (1, 2) can further exhibit an additive effect on the elimination of
agglutinated MRBC from livers and spleens. The absence of these activities, there-
fore preventing a rapid removal of agglutinated RBC, would account for the devel-
opment of fibrosis around necrotic tissuesobserved in spleensandlivers of surviving
mice perfused with rEpo. Clearly, these effects on macrophages are by themselves
insufficient to insure protection, as shown by the inefficiency of rGM-CSF, which
has similar effects on the monocyte/macrophage lineage (10, 11). Finally, one may
wonder whether the perfusion with rIL-3 or rEpo starting before the anti-MRBC
mAb injection allows a rapid rise in RBC that absorb some of anti-MRBC mAb,
thereby markedly diminishing consequent accumulation of agglutinated RBC in
spleens and livers. The successful treatment of acute severe anemia by rIL-3 sug-
gests that such a therapeutic approach might be considered in combination with
Epo in some patients with acute severe form of hemolytic anemia, in whom the dis-
order is refractory to standard forms of therapy.
Summary
We have evaluated the therapeutic activity of HL-3, in comparison with recom-
binant granulocyte-macrophage CSF (rGM-CSF) and recombinant erythropoietin
(rEpo), on a lethal form of acute anemia induced by a single injection of a mono-
clonal IgGI anti-mouse RBC (MRBC) autoantibody. Continuous perfusionof HL-3
before the administration of anti-MRBC mAb prevented animals from the death
due to anemia with a rapid recovery in >90% ofthecases, while only partial protec-
tion (one third of the cases) was obtained by rEpo perfusion, and no protection by
rGM-CSF. Since the anti-MRBC mAb induced a marked agglutination of RBC
in spleens and livers, and subsequent hemodynamic failure may be an additional
contributing factor to the animals' death, the activation of Fc-y receptor-dependent
phagocytosis by rIL-3, as well as the increased number of monocytes/macrophages
resulting from rIL-3 perfusion, may also facilitate rapid elimination ofthese agglu-
tinatedRBC, resulting in the further amelioration oftheanimals' survival. Ourresults1814
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suggest that the therapeutic effect of rIL-3 on anti-MRBC autoantibody-induced
anemia is achieved by: (a) its activity to promote the growth and differentiation of
erythroid progenitors responsive to Epo and of monocyte/macrophage lineage; and
(b) its activity to enhance the phagocytic activity ofmacrophages to efficiently elimi-
nate agglutinated RBC in spleens and livers.
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